These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 15454492)

  • 1. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.
    Walter RB; Raden BW; Kamikura DM; Cooper JA; Bernstein ID
    Blood; 2005 Feb; 105(3):1295-302. PubMed ID: 15454492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.
    Linenberger ML
    Leukemia; 2005 Feb; 19(2):176-82. PubMed ID: 15592433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
    Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
    Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
    Walter RB; Gooley TA; van der Velden VH; Loken MR; van Dongen JJ; Flowers DA; Bernstein ID; Appelbaum FR
    Blood; 2007 May; 109(10):4168-70. PubMed ID: 17227830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
    Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS
    J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
    Balaian L; Ball ED
    Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.
    Petrich T; Korkmaz Z; Krull D; Frömke C; Meyer GJ; Knapp WH
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):851-61. PubMed ID: 20107790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells.
    van Der Velden VH; te Marvelde JG; Hoogeveen PG; Bernstein ID; Houtsmuller AB; Berger MS; van Dongen JJ
    Blood; 2001 May; 97(10):3197-204. PubMed ID: 11342449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells.
    Yamauchi T; Matsuda Y; Tasaki T; Negoro E; Ikegaya S; Takagi K; Yoshida A; Urasaki Y; Ueda T
    Cancer Sci; 2012 Sep; 103(9):1722-9. PubMed ID: 22632031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.
    Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH
    Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.
    ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W
    Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
    Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
    Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
    Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
    Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.
    van der Velden VH; Boeckx N; Jedema I; te Marvelde JG; Hoogeveen PG; Boogaerts M; van Dongen JJ
    Leukemia; 2004 May; 18(5):983-8. PubMed ID: 15029214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.
    Chevallier P; Mahe B; Garand R; Talmant P; Harousseau JL; Delaunay J
    Int J Hematol; 2008 Sep; 88(2):209-211. PubMed ID: 18668307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study.
    Lamba JK; Pounds S; Cao X; Downing JR; Campana D; Ribeiro RC; Pui CH; Rubnitz JE
    Leukemia; 2009 Feb; 23(2):402-4. PubMed ID: 18615103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.
    Walter RB; Raden BW; Hong TC; Flowers DA; Bernstein ID; Linenberger ML
    Blood; 2003 Aug; 102(4):1466-73. PubMed ID: 12689934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia.
    Nabhan C; Tallman MS
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S19-23. PubMed ID: 11970766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
    ten Cate B; Samplonius DF; Bijma T; de Leij LF; Helfrich W; Bremer E
    Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.